Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Darinaparsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Solasia Pharma
- 26 Dec 2017 Planned End Date changed from 1 Jun 2018 to 1 Mar 2019.
- 26 Dec 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
- 28 Mar 2016 Based on the results of this trial, Solasia intends to file for registration in Japan, South Korea, Taiwan and Hong Kong according to a company media release.